 | |
| Formation | 1995 |
|---|---|
| Founders | |
| Legal status | Charity |
| Purpose | To prevent, treat, and cure urology diseases |
| Headquarters | 1-2 St Andrew's Hill, London EC4V 5BY |
| Origins | |
| Methods |
|
| Fields | Diseases of the male and female urinary-tract system and the male reproductive organs |
President | Roger Kirby |
Chairman | Paul Fletcher |
Chief Executive | Louise de Winter |
Ambassador | Stephen Fry |
| Secessions | |
| Website | Official website |
Formerly called | The British Urological Foundation |
The Urology Foundation (TUF) is a charity that works across the UK and Ireland with the aim of improving the knowledge and skills of surgeons who operate on diseases of the male and female urinary-tract system and the male reproductive organs and funds research to improve outcomes of all urological conditions and urological cancers.
Its work is solely supported by donations. By financing research, it develops diagnostic tests and minimally invasive procedures for urological diseases. By supporting training, it improves surgical skills, and by awarding grants it provides opportunities for surgeons to travel to various parts of the world and practise new techniques.
TUF was founded under the banner of 'The British Urological Foundation' in 1995 by urologists Roger Kirby and John M. Fitzpatrick, and introduced robotic surgical training for urologists in 2011. It holds teaching sessions to prepare final year trainees for consultant posts and works in collaboration with the Fulbright Commission to grant 'The Fulbright Urology Foundation Award', for a research assignment in an academic higher education institution in the States. Projects granted funding by TUF have included those concentrating on cancers of the prostate, bladder and kidney, sexual dysfunction, urinary incontinence, BPH and prostatitis.
TUF organises a number of fundraising and awareness events, including their 'Annual Urology Awareness Month' and charity bike rides. Its contributions have included funding into the research of a tool developed to predict a person's personalised prognosis following a diagnosis of prostate cancer.